2025 ACMG Annual Clinical Genetics Meeting

2025 ACMG Annual Clinical Genetics Meeting

March 18 – 22 | Los Angeles, California

The 2025 ACMG Annual Clinical Genetics Meeting will gather members of the medical genetics community from around the world to learn, connect and celebrate together in Los Angeles, California. This four-day meeting offers unique and valuable opportunities to forge meaningful connections, share interests and celebrate achievements, while hearing about new discoveries in genetic disorders, rare diseases, genome sequencing, gene therapies and best practices in genetic counseling.

Registration, housing, and abstract submission open on October 1, 2024. To learn more and stay updated on meeting information, visit the ACMG meeting websitePlease note: Registration is required.

Integrating Genetics into the Tanzanian Healthcare: An Overview

Integrating Genetics into the Tanzanian Healthcare: An Overview

Tuesday, May 28 | 9 a.m. ET | Virtual

Speaker: Dr. Mohamed Zahir Alimohamed

Dr. Alimohamed will provide an overview of the current landscape and future prospects of integrating genetics into healthcare practices in Tanzania, beginning by outlining the existing healthcare infrastructure and genetic services available in the country. Next, Dr. Alimohamed will discuss the challenges and opportunities faced in implementing genetic testing, counseling, and treatment options within the Tanzanian healthcare system.

To learn more and register, visit the GGMC Educational Webinar Series webpage.

Please note: Registration is required for this webinar.

Development and Validation of the Minnesota Assessment of Pharmacogenomic Literacy (MAPL)

Josiah D Allen, Lusi Zhang, Alyssa N K Johnson, Pamala A Jacobson, Catherine A McCarty, Amy L Pittenger, Jeffrey R Bishop

Abstract
Ensuring that patients have an adequate understanding of pharmacogenomic (PGx) test results is a critical component of implementing precision medicine into clinical care. However, no PGx-specific validated literacy assessment has yet been developed. To address this need, we developed and validated the Minnesota Assessment of Pharmacogenomic Literacy (MAPLTM). Foundational work included a scoping review of patient and general public attitudes and experiences with pharmacogenomic testing, three focus groups, readability assessments, and review by experts and members of the general public. This resulted in a 15-item assessment designed to assess knowledge in four domains: underlying concepts, limitations, benefits, and privacy. For validation, 646 participants completed the MAPL as a part of a larger survey about pharmacogenomic research and statewide PGx implementation. Two items were deemed to be “too easy” and dropped. The remaining 13 items were retained in the final MAPL with good internal reliability (Cronbach’s alpha = 0.75). Confirmatory factor analysis validated the four-domain construct of MAPL and suggested good model performance and high internal validity. The estimated coefficient loadings across 13 questions on the corresponding domains are all positive and statistically significant (p < 0.05). The MAPL covers multiple knowledge domains of specific relevance to PGx and is a useful tool for clinical and research settings where quantitative assessment of PGx literacy is of value.

Keywords: genetic counseling; genomic literacy; literacy assessment; pharmacogenomics; psychometric validation.